BCL2 and AL amyloidosis: Based on our results, highly primed clonal plasma cells from patients with AL amyloidosis would be sensitive to single agent treatment with a proteasome inhibitor, dexamethasone, or an inhibitor of MCL-1 or BCL-2, especially, when treatments are assigned with biomarkers such as BH3 profiling (Fig. S3).